The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Abstract
The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase. Activating mutations of SHP2 have been associated with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukaemia, lung and breast cancer and neuroblastoma. SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS–ERK signalling pathway. It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways. Reduction of SHP2 activity suppresses tumour cell growth and is a potential target of cancer therapy. Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-molecule SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation. SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumour xenograft models. Together, these data demonstrate that pharmacological inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inhibition of SHP2 is seen as a promising strategy for treating several receptor tyrosine kinase-driven cancers [52].”
From The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling (2021) · cites this paper as [52]
In the citing paper
“To further verify the role of Stat3 and Shp2 in regulating the IL-6/Morrbid axis in Tet2-KO Lin-negative cells, we treated the cells with E3330, a pan inhibitor of both NFκB and Stat3 (Cardoso et al., 2012; Jedinak et al., 2011), and SHP099, a novel selective allosteric inhibitor of Shp2 (Chen et al., 2016).”
From Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis (2018) · cites this paper as Chen et al., 2016
In the citing paper
“Using NI-1 as a template compound, PCC0208023 was designed via a scaffold hopping strategy.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [287]
In the citing paper
“The reporting of SHP099 is a milestone for small molecule SHP2 allosteric inhibitors, which further led to the development of aforementioned SHP2 inhibitor in clinical trials, TNO-155.286,287”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [287]
In the citing paper
“This mechanism of action inhibits SHP2 activity through a metastable mechanism, leading to the inhibition of RAS/ERK signaling and suppressing RTK-driven proliferation of human cancer cells in vitro.286–288”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [287]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Self-citationCrystal Structure of the Tyrosine Phosphatase SHP-2
Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J., & Shoelson, S. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80938-1 · Cited by 985
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Protein-tyrosine phosphatases and cancer
Östman, A., Hellberg, C., & Böhmer, F. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1837 · Cited by 657
Hoffman, G. R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316793111 · Cited by 421
Self-citationPTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Chan, R. J., & Feng, G.-S. (2007) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 371
Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S., & Jenkins, J. L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700026 · Cited by 327
Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains
Pluskey, S., Wandless, T. J., Walsh, C. T., & Shoelson, S. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.7.2897 · Cited by 282
Cited by
Next-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
Self-citationPROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
“nonreceptor type 11 (PTPN11; also known as SHP2) inhibitor SHP099 (reF.(230)), which stabilizes a closed conformation of SHP2 (intramolecular); and cyclosporin(231),”
BackgroundExploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Metadata
- Authors
- Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., Dobson, J. R., Deng, Z., Fei, F., Firestone, B., Fodor, M., Fridrich, C., Gao, H., Grunenfelder, D., Hao, H.-X., Jacob, J., Ho, S., Hsiao, K., Kang, Z. B., Karki, R., Kato, M., Larrow, J., La Bonte, L. R., Lenoir, F., Liu, G., Liu, S., Majumdar, D., Meyer, M. J., Palermo, M., Perez, L., Pu, M., Price, E., Quinn, C., Shakya, S., Shultz, M. D., Slisz, J., Venkatesan, K., Wang, P., Warmuth, M., Williams, S., Yang, G., Yuan, J., Zhang, J.-H., Zhu, P., Ramsey, T., Keen, N. J., Sellers, W. R., Stams, T., & Fortin, P. D.
- Corresponding author
- Sellers, William R.
- Stams, Travis
- Fortin, Pascal D.
- ORCID
- LaMarche, Matthew J.
- Chan, Ho Man
- Acker, Michael G.
- Dobson, Jason R.
- Deng, Zhan
- Hao, Huai-Xiang
- Ho, Samuel
- Kato, Mitsunori
- Larrow, Jay
- Liu, Gang
- Liu, Shumei
- Meyer, Matthew J.
- Price, Edmund
- Quinn, Christopher
- Shultz, Michael D.
- Slisz, Joanna
- Venkatesan, Kavitha
- Williams, Sarah
- Yuan, Jing
- Zhu, Ping
- Keen, Nicholas J.
- Sellers, William R.
- Fortin, Pascal D.
- Venue
- Nature
- Published
- 2016-06-29
- Volume
- 535
- Issue
- 7610
- Pages
- 148-152
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2468923062
- Cited by
- 925
- References
- 28
- Citations by year
- 2026: 82 · 2025: 96 · 2024: 93 · 2023: 121 · 2022: 99 · 2021: 125 · 2020: 99 · 2019: 78 · 2018: 61 · 2017: 57 · 2016: 13
- FWCI
- 36.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- SHP2, SHP099, allosteric inhibition, receptor tyrosine kinase signaling, cancer therapy, oral bioavailability, tumor xenografts, immune checkpoint, Noonan syndrome, small molecule inhibitors, PTPN11, tumor cell proliferation
- MeSH terms
- Allosteric Regulation, Animals, Female, Humans, Mice, Nude, Models, Molecular, Neoplasms, Piperidines, Pyrimidines, Reproducibility of Results, Oncogene Protein p21(ras), Protein Structure, Tertiary, Inhibitory Concentration 50, Receptor Protein-Tyrosine Kinases, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Protein Stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. https://app.cochat.ai/papers/10.1038/nature18621
- The paper
- Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., Dobson, J. R., Deng, Z., Fei, F., Firestone, B., Fodor, M., Fridrich, C., Gao, H., Grunenfelder, D., Hao, H.-X., . . . Fortin, P. D. (2016). Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. https://doi.org/10.1038/nature18621
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.